1. Home
  2. Stocks
  3. Biocon Share Price

BIOCON

Large Cap BSE: 532523 NSE: BIOCON
₹290.95
4.1 (1.43%)
  • Advice
  • Hold
As on 01 October, 2022 | 08:10
Announcements Dividends

Biocon Share Price

Biocon Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in BIOCON

Start SIP
Share Returns Investment Rating Financials
More
Technicals Resistance and Support Delivery and Volume Result Highlights Synopsis Corporate Action MF Shareholding Similar Stocks News FAQs

Biocon Share Returns

  • Over 1 Month -6.11%
  • Over 3 Month -5.66%
  • Over 6 Month -14.81%
  • Over 1 Year -19.78%

Biocon Key Statistics

P/E Ratio 49.3
PEG Ratio 10.1
Market Cap Cr 34,932
Price to Book Ratio 3.7
EPS 0.7
Dividend 0.2
Relative Strength Index 46.05
Money Flow Index 41.47
MACD Signal -5.88
Average True Range 7.32

Biocon Investment Rating

  • Master Rating:

  • Biocon (Nse) has an operating revenue of Rs. 8,562.90 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 15% is great, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 47%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 16 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 155 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Biocon Financials
IndicatorJun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 442518473365383492
Operating Expenses Qtr Cr 439491439388359425
Operating Profit Qtr Cr 32734-232467
Depreciation Qtr Cr 292828272625
Interest Qtr Cr 000000
Tax Qtr Cr 82118-31719
Net Profit Qtr Cr 153826-72968

Biocon Technicals

EMA & SMA

Current Price
290.95
4.1 (1.43%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 292.44
  • 50 Day
  • 302.6
  • 100 Day
  • 314.97
  • 200 Day
  • 338.21
  • 20 Day
  • 293.1
  • 50 Day
  • 304.72
  • 100 Day
  • 314.88
  • 200 Day
  • 338.25

Biocon Resistance and Support

PIVOT
₹286.61
Resistance
First Resistance 288.95
Second Resistance 291.05
Third Resistance 293.4
RSI 46.05
MFI 41.47
MACD Single Line -5.88
MACD -5.91
Support
First Resistance 284.5
Second Resistance 282.15
Third Resistance 280.05

Biocon Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,975,124 85,088,342 43.08
Week 1,724,967 56,440,907 32.72
1 Month 2,113,903 92,462,131 43.74
6 Month 2,284,977 74,970,111 32.81

Biocon Result Highlights

Biocon Synopsis

NSE-Medical-Biomed/Biotech

Biocon is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1738.20 Cr. and Equity Capital is Rs. 600.30 Cr. for the Year ended 31/03/2022. Biocon Ltd. is a Public Limited Listed company incorporated on 29/11/1978 and has its registered office in the State of Karnataka, India. Company’s Corporate Identification Number(CIN) is L24234KA1978PLC003417 and registration number is 003417.
Market Cap 34,931
Sales 1,797
Shares in Float 46.82
No of funds 504
Yield 0.17
Book Value 4.32
U/D Vol ratio 0.7
LTDebt / Equity 1
Alpha -0.07
Beta 0.79

Biocon

Owner NameJun-22Mar-22Dec-21Sep-21
Promoters 60.64%60.64%60.64%
Mutual Funds 3.05%3.52%2.54%
Insurance Companies 4.25%4.25%4.24%
Foreign Portfolio Investors 16.31%15.62%16%
Financial Institutions/ Banks 0.02%0.05%
Individual Investors 10.72%10.87%11.36%
Others 5.03%5.08%5.17%

Biocon Management

Name Designation
Mr. Siddharth Mittal Managing Director & CEO
Ms. Kiran Mazumdar Shaw Executive Chairperson
Mr. John Shaw Vice Chairman & Non Exe.Dire
Prof. Ravi Mazumdar Non Executive Director
Mr. Mary Harney Independent Director
Mr. Daniel M Bradbury Independent Director
Dr. Vijay Kuchroo Independent Director
Mr. M Damodaran Independent Director
Mr. Bobby Kanubhai Parikh Independent Director

Biocon Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Biocon Corporate Action

Date Purpose Remarks
2022-07-27 Quarterly Results
2022-04-28 Audited Results & Dividend
2022-01-20 Quarterly Results
2021-10-21 Quarterly Results
2021-07-22 Quarterly Results
Date Purpose Remarks
2022-07-01 FINAL Rs.0.50 per share(10%)Final Dividend

Biocon MF Shareholding

Name Amount(cr)
Mirae Asset Large Cap Fund Regular Growth 33747
ICICI Prudential Bluechip Fund Growth 33739
Kotak Equity Arbitrage Fund Growth 23310
Kotak Balanced Advantage Fund Regular Growth 14587
Aditya Birla Sun Life Tax Relief 96 Pyt of Inc Dis cum Cap Wdrl 14201

About Company

Biocon limited is a biopharmaceutical company in India and it is Asia's largest biotechnology company. The company was founded by Kiran Mazumdar-Shaw in 1978 and is headquartered in Bangalore, India. The company has more than 13,500  employees. It focuses on all phases of the product cycle from researching to development and then introducing them to the market.  They mainly concentrate on the research and development of advanced therapies for the treatment of cancer, diabetes, and autoimmune disease. The company's medicines are helping the lives of patients in more than 120 countries by providing access to all their medicines and therapies. 

Some of Biocon's important brands in India are INSUGEN (rh-insulin), BIOMAb EGFR (Nimotuzumab), CANMAb (Trastuzumab),KRABEVA (Bevacizumab), ALZUMAb(Itolizumab), BLISTO (Glimepiride + Metformin), BASALOG (Glargine), etc. 

 

History of Biocon limited 


Biocon Limited was incorporated in 1978. It is  India's largest pharmaceutical company. During incorporation, it was a joint venture between Biocon Biochemicals Limited Ireland and an Indian entrepreneur Kiran Mazumdar-Shaw. Biocon started its journey by exporting enzymes to the USA and Europe.

In the year 1989 Unilever Acquired Biocon’s Irish Parent and merged with Quest International. 

In 2004, Biocon limited entered into a 9-year contract with the US to supply recombinant human insulin and in July 2004, the company said that its Cuban partner CIMAB ( center for molecular immunology ) with Biocon licensed out three experimental cancer drugs to a Biotechnology Company, CancerVax. 

In 2005, Biocon signed a memorandum of understanding with the Karolinska Institute. The CMD of Biocon Limited, Kiran Mazumdar-Shaw was honoured with the corporate leadership award. 

In 2006, The company tied up with ICICI prudential life insurance and finished phase-4 trials of insulin. 

In 2009, Biocon joined hands with Mylan pharmaceuticals.

In 2010, The company invested in Malaysia partnering with Biotechcorp. 

Biocon FAQs

What is Share Price of Biocon ?

Biocon share price is ₹290 As on 01 October, 2022 | 07:56

What is the Market Cap of Biocon ?

The Market Cap of Biocon is ₹34931.5 Cr As on 01 October, 2022 | 07:56

What is the P/E ratio of Biocon ?

The P/E ratio of Biocon is 49.3 As on 01 October, 2022 | 07:56

What is the PB ratio of Biocon ?

The PB ratio of Biocon is 3.7 As on 01 October, 2022 | 07:56

Is it a good time to invest in Biocon Limited?

Biocon has an operating revenue of Rs.7,290.70 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 16% is great. However, analysts are of mixed views on the stock.

How many times has Biocon Limited given dividends since 2004?

Biocon Ltd. has declared 17 dividends since July 1, 2004.

What is the stock price CAGR of Biocon Limited?

The stock price CAGR of Biocon Limited for 10 Years is 24%, 5 Years is 17%, 3 Years is 5%, 1 Year is -21%.

What is the debt-to-equity ratio of Biocon Limited?

The debt-to-equity ratio of Biocon Limited is 39% which signals a healthy balance sheet.

What is the ROE of the Biocon Limited?

The ROE of Biocon Limited is 9% which is fair but needs improvement.

Who is the Managing Director of Biocon Limited?

Mr. Siddharth Mittal is the Managing Director and CEO of Biocon Limited.

Is Biocon a good stock to buy?

According to the record analysis of moneyworks4me, Biocom limited is an average quality company. 

What is the revenue of Biocon?

The revenue of Biocon for FY22 is Rs. 8184 Cr.

How to buy shares of Biocon Ltd?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q1FY23
Open Demat Account